Loading…

Crossing the HLA barriers

Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favor...

Full description

Saved in:
Bibliographic Details
Published in:Blood cells, molecules, & diseases molecules, & diseases, 2004-11, Vol.33 (3), p.206-210
Main Authors: Reisner, Yair, Gur, Hilit, Reich-Zeliger, Shlomit, Martelli, Massimo F., Bachar-Lustig, Esther
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3
cites cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3
container_end_page 210
container_issue 3
container_start_page 206
container_title Blood cells, molecules, & diseases
container_volume 33
creator Reisner, Yair
Gur, Hilit
Reich-Zeliger, Shlomit
Martelli, Massimo F.
Bachar-Lustig, Esther
description Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34 + cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34 + cells. Early myeloid CD33 + cells generated by short-term ex vivo expansion of CD34 + cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8 + CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.
doi_str_mv 10.1016/j.bcmd.2004.08.004
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67044312</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1079979604001627</els_id><sourcerecordid>67044312</sourcerecordid><originalsourceid>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqXwA2BAndgSzo6d2BJLVQFFqsQCs-XYF3DVNMVOkPj3OGolNobTu-G9p7uPkBsKOQVa3m_y2rYuZwA8B5knOSFTCqrM0tDTca9UpipVTshFjBsAoFTJczKhQjBJCzYl18vQxeh3H_P-E-er9WJemxA8hnhJzhqzjXh11Bl5f3p8W66y9evzy3KxzmwhWJ9hzctGMVs6AJRohZDWgOTADYqCV1ZVwEXFRGMFSGEa5oCx0qnC1bVxtpiRu0PvPnRfA8Zetz5a3G7NDrsh6jLleUFZMrKD0Y4nB2z0PvjWhB9NQY9A9EaPQPQIRIPUSVLo9tg-1C26v8iRQDI8HAyYfvxOj-toPe4sOh_Q9tp1_r_-X-USbw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67044312</pqid></control><display><type>article</type><title>Crossing the HLA barriers</title><source>ScienceDirect Journals</source><creator>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</creator><creatorcontrib>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</creatorcontrib><description>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34 + cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34 + cells. Early myeloid CD33 + cells generated by short-term ex vivo expansion of CD34 + cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8 + CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</description><identifier>ISSN: 1079-9796</identifier><identifier>EISSN: 1096-0961</identifier><identifier>DOI: 10.1016/j.bcmd.2004.08.004</identifier><identifier>PMID: 15528132</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Antigens, CD34 - immunology ; Bone marrow ; Graft vs Host Disease - immunology ; Hematopoietic Stem Cell Transplantation ; Histocompatibility - immunology ; HLA Antigens - immunology ; Humans ; Mice ; Nonmyeloablative conditioning ; T-Lymphocytes, Cytotoxic - immunology ; Tolerance ; Transplantation Immunology</subject><ispartof>Blood cells, molecules, &amp; diseases, 2004-11, Vol.33 (3), p.206-210</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</citedby><cites>FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15528132$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reisner, Yair</creatorcontrib><creatorcontrib>Gur, Hilit</creatorcontrib><creatorcontrib>Reich-Zeliger, Shlomit</creatorcontrib><creatorcontrib>Martelli, Massimo F.</creatorcontrib><creatorcontrib>Bachar-Lustig, Esther</creatorcontrib><title>Crossing the HLA barriers</title><title>Blood cells, molecules, &amp; diseases</title><addtitle>Blood Cells Mol Dis</addtitle><description>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34 + cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34 + cells. Early myeloid CD33 + cells generated by short-term ex vivo expansion of CD34 + cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8 + CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</description><subject>Animals</subject><subject>Antigens, CD34 - immunology</subject><subject>Bone marrow</subject><subject>Graft vs Host Disease - immunology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Histocompatibility - immunology</subject><subject>HLA Antigens - immunology</subject><subject>Humans</subject><subject>Mice</subject><subject>Nonmyeloablative conditioning</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Tolerance</subject><subject>Transplantation Immunology</subject><issn>1079-9796</issn><issn>1096-0961</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp9kDFPwzAQhS0EoqXwA2BAndgSzo6d2BJLVQFFqsQCs-XYF3DVNMVOkPj3OGolNobTu-G9p7uPkBsKOQVa3m_y2rYuZwA8B5knOSFTCqrM0tDTca9UpipVTshFjBsAoFTJczKhQjBJCzYl18vQxeh3H_P-E-er9WJemxA8hnhJzhqzjXh11Bl5f3p8W66y9evzy3KxzmwhWJ9hzctGMVs6AJRohZDWgOTADYqCV1ZVwEXFRGMFSGEa5oCx0qnC1bVxtpiRu0PvPnRfA8Zetz5a3G7NDrsh6jLleUFZMrKD0Y4nB2z0PvjWhB9NQY9A9EaPQPQIRIPUSVLo9tg-1C26v8iRQDI8HAyYfvxOj-toPe4sOh_Q9tp1_r_-X-USbw4</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Reisner, Yair</creator><creator>Gur, Hilit</creator><creator>Reich-Zeliger, Shlomit</creator><creator>Martelli, Massimo F.</creator><creator>Bachar-Lustig, Esther</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Crossing the HLA barriers</title><author>Reisner, Yair ; Gur, Hilit ; Reich-Zeliger, Shlomit ; Martelli, Massimo F. ; Bachar-Lustig, Esther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antigens, CD34 - immunology</topic><topic>Bone marrow</topic><topic>Graft vs Host Disease - immunology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Histocompatibility - immunology</topic><topic>HLA Antigens - immunology</topic><topic>Humans</topic><topic>Mice</topic><topic>Nonmyeloablative conditioning</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Tolerance</topic><topic>Transplantation Immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reisner, Yair</creatorcontrib><creatorcontrib>Gur, Hilit</creatorcontrib><creatorcontrib>Reich-Zeliger, Shlomit</creatorcontrib><creatorcontrib>Martelli, Massimo F.</creatorcontrib><creatorcontrib>Bachar-Lustig, Esther</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood cells, molecules, &amp; diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reisner, Yair</au><au>Gur, Hilit</au><au>Reich-Zeliger, Shlomit</au><au>Martelli, Massimo F.</au><au>Bachar-Lustig, Esther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Crossing the HLA barriers</atitle><jtitle>Blood cells, molecules, &amp; diseases</jtitle><addtitle>Blood Cells Mol Dis</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>33</volume><issue>3</issue><spage>206</spage><epage>210</epage><pages>206-210</pages><issn>1079-9796</issn><eissn>1096-0961</eissn><abstract>Studies in mice and humans demonstrate that transplantation of hematopoietic progenitors in numbers larger than commonly used (“megadose” transplants) overcomes major genetic barriers. In vitro studies suggest that veto cells, within the population of hematopoietic progenitors, facilitate this favorable outcome. Thus, when purified CD34 + cells were added to bulk mixed-lymphocyte reactions (MLRs), they suppressed CTLs against donor's stimulators but not against stimulators from a third party. This tolerizing activity depends on cell contact and can be blocked by the caspase inhibitor BD-FMK, suggesting that the effector host T cells are deleted by apoptosis upon interaction with the CD34 + cells. Early myeloid CD33 + cells generated by short-term ex vivo expansion of CD34 + cells also exhibit veto activity, and these cells can be grown in large numbers. Tolerance induction can be further enhanced by other veto cells. Perhaps the most potent veto cell is the CD8 + CTL. However, this cell is also associated with marked graft-versus-host disease (GVHD). GVHD can be separated from the veto activity by generating anti-third party CTLs under IL2 deprivation. Under such selective pressure, only the stimulated clones which make IL2 can survive, while anti-host clones die. In vivo studies show that such anti-third party veto CTLs can be used safely for tolerance induction without GVHD.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15528132</pmid><doi>10.1016/j.bcmd.2004.08.004</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1079-9796
ispartof Blood cells, molecules, & diseases, 2004-11, Vol.33 (3), p.206-210
issn 1079-9796
1096-0961
language eng
recordid cdi_proquest_miscellaneous_67044312
source ScienceDirect Journals
subjects Animals
Antigens, CD34 - immunology
Bone marrow
Graft vs Host Disease - immunology
Hematopoietic Stem Cell Transplantation
Histocompatibility - immunology
HLA Antigens - immunology
Humans
Mice
Nonmyeloablative conditioning
T-Lymphocytes, Cytotoxic - immunology
Tolerance
Transplantation Immunology
title Crossing the HLA barriers
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A18%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Crossing%20the%20HLA%20barriers&rft.jtitle=Blood%20cells,%20molecules,%20&%20diseases&rft.au=Reisner,%20Yair&rft.date=2004-11-01&rft.volume=33&rft.issue=3&rft.spage=206&rft.epage=210&rft.pages=206-210&rft.issn=1079-9796&rft.eissn=1096-0961&rft_id=info:doi/10.1016/j.bcmd.2004.08.004&rft_dat=%3Cproquest_cross%3E67044312%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c352t-eb46f92c6d00e8ec558ca08404ae5347c97045725fc5085af2d0226d93dbbadc3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67044312&rft_id=info:pmid/15528132&rfr_iscdi=true